Human Blood for Research Utilizing Malaria Parasite Cultures

The Defense Health Agency is seeking screened human blood products through a Request for Information to support malaria parasite research conducted by the Walter Reed Army Institute of Research's Biologics Research and Development Branch. The procurement requires blood products collected in the United States from FDA-registered donors with comprehensive testing for multiple infectious diseases including HIV, HBV, HCV, HTLV, syphilis, Chagas, West Nile, and Zika viruses. Blood must be collected using CPDA-1 anticoagulant from donors who have not taken antimalarial drugs or aspirin within specified timeframes, with serum and whole blood delivered via Priority Overnight shipping within 5-7 days of donation. Capability statements are limited to 15 pages and must demonstrate the respondent's ability to meet detailed blood product screening and delivery specifications. The submission deadline is 11:00am EST on September 12, 2025, with responses required via email to joshua.r.dean2.civ@health.mil.

This opportunity does not include any set-aside designation and no current contractors or incumbents are identified in the documentation. The potential performance period spans five years from November 2025 to November 2030, though no specific award values or budget ranges are disclosed in the RFI. The document explicitly states this is an information-gathering exercise only, with no contract to be awarded directly from this solicitation and no unsolicited proposals will be considered. The procurement falls under NAICS code 325414 for Biological Product Manufacturing and PSC code 6506 for Blood and Blood Products. Interested parties must demonstrate their capability to meet the stringent FDA compliance requirements and specialized delivery timelines for research-grade blood products.